<DOC>
	<DOC>NCT00236899</DOC>
	<brief_summary>Multi-center, randomized Phase III study. 4 arms. 360 Patient to enroll. Purpose is evaluate time to progression disease (PD).</brief_summary>
	<brief_title>Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologic diagnosis of metastatic breast cancer (MBC). Prior neoadjuvant or adjuvant taxanes regimen is allowed if â‰¥12 months since completion of the regimen. Relapsing after receiving one adjuvant/neoadjuvant chemotherapy containing an anthracycline if not clinically contraindicated. Patients with measurable disease. Previous hormonal therapy for adjuvant setting or metastatic disease. Previous chemotherapy for MBC Previous chemotherapy with gemcitabine in any setting of disease Patient candidable to treatment with trastuzumab.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>